Pharminent

Circassia signs deal for US rights to two AstraZeneca COPD drugs

UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD). http://drugdiscovery.pharmaceutical-business-review.com/news/circassia-secures-us-rights-for-two-astrazeneca-copd-drugs-for-230m-200317-5766626

Filed under: COPD